Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008)

Annals of Clinical Microbiology and Antimicrobials

Volumn 13, Issue 1, 2014, Pages

  Tomic, Viktorija ^a   Dowzicky, Michael J ^b  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial susceptibility; Haemophilus influenzae; Streptococcus pneumoniae; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFEPIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; BROTH DILUTION; EUROPE; HAEMOPHILUS INFLUENZAE; HUMAN; MIDDLE EAST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PENICILLIN RESISTANCE; PHENOTYPE; SOUTH AFRICA; SOUTH AND CENTRAL AMERICA; STREPTOCOCCUS PNEUMONIAE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; HAEMOPHILUS INFECTION; HEALTH; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PNEUMOCOCCAL INFECTION;

ANTI-BACTERIAL AGENTS; GLOBAL HEALTH; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84924405550     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-014-0052-2     Document Type: Article

References (27)

1. European Centre for Disease Prevention and Control: Antimicrobial resistance surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control; 2012.
2. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, Lukšić I, Fischer Walker CL, Black RE, Campbell H, Child Health Epidemiology Reference Group (CHERG): Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013, 3:10401.
3. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
4. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJ, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases: Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect 2011, 17(Suppl 6):E1-E59.
5. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, Macfarlane JT, Read RC, Roberts HJ, Levy ML, Wani M, Woodhead MA, Pneumonia Guidelines Committee of the BTS Standards of Care Committee: BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009, 64(Suppl 3):iii1-iii55.
6. Spindler C, Strålin K, Eriksson L, Hjerdt-Goscinski G, Holmberg H, Lidman C, Nilsson A, Ortqvist A, Hedlund J, Community Acquired Pneumonia Working Group of The Swedish Society of Infectious Diseases: Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults-Swedish Society of Infectious Diseases 2012. Scand J Infect Dis 2012, 44:885-902.
7. Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, Schouten JA, Degener JE, Janknegt R, Verheij TJ, Sachs AP, Prins JM, Dutch Working Party on Antibiotic Policy; Dutch Association of Chest Physicians: SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults. Neth J Med 2012, 70:90-101.
8. Niederman MS, Luna CM: Community-acquired pneumonia guidelines: a global perspective. Semin Respir Crit Care Med 2012, 33:298-310.
9. Cilli A: The yield of tigecycline in the treatment of community-acquired pneumonia. Tuberk Toraks 2013, 61:155-161.
10. US Food and Drug Administration (FDA): Tigecycline label, 20 March 2009. Rockville, MD: US Food and Drug Administration; 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf.
11. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R, 308 Study Group, 313 Study Group: Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008, 61:329-338.
12. Darabi A, Hocquet D, Dowzicky MJ: Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis 2010, 67:78-86.
13. th ed. Document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
14. Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard: 8th edition. Document M7-A8. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
15. Pfizer Inc. (Wyeth Pharmaceuticals): Tygacil® Product Insert [Internet]. Philadelphia, PA: Pfizer Inc., 2013. http://www.pfizerpro.com/hcp/tygacil
16. Jones RN, Sader HS, Mendes RE, Flamm RK: Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013, 75:107-109.
17. Weinstein MP, Klugman KP, Jones RN: Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009, 48:1596-1600.
18. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV: Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 2013, 19:1074-1083.
19. Flamm RK, Sader HS, Jones RN: Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. Braz J Infect Dis 2013, 17:564-572.
20. Zhao C, Sun H, Wang H, Liu Y, Hu B, Yu Y, Sun Z, Chu Y, Cao B, Liao K, Lei J, Hu Z, Zhang L, Zhang X, Xu Y, Wang Z, Chen M: Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010). Diagn Microbiol Infect Dis 2012, 73:174-181.
21. Nilsson LE, Frimodt-Møller N, Vaara M, Simonsen GS, Tigecycline Study Group: Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries. Scand J Infect Dis 2011, 43:707-713.
22. Liñares J, Ardanuy C, Pallares R, Fenoll A: Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010, 16:402-410.
23. Jinno S, Jacobs MR: Pneumonia due to drug-resistant Streptococcus pneumoniae. Curr Infect Dis Rep 2012, 14:292-299.
24. Jones RN, Farrell DJ, Mendes RE, Sader HS: Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011, 66(Suppl 3):iii69-iii80.
25. Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Levofloxacin-Surveillance Group: In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010. Jpn J Antibiot 2012, 65:181-206.
26. Fluit AC, Florijn A, Verhoef J, Milatovic D: Susceptibility of European β-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003. J Antimicrob Chemother 2005, 56:133-138.
27. Heilmann KP, Rice CL, Miller AL, Miller NJ, Beekmann SE, Pfaller MA, Richter SS, Doern GV: Decreasing prevalence of β-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 2005, 49:2561-2564.